Jennifer Onyekonwu-Mcgill, NP
Psychiatric/Mental Health · Claremont, CANPI 1063686616
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 1,108 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,108 payments — averaging $20.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$5K
- Alkermes, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Johnson & Johnson$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$2K
- plus $8K from 23 others
What the payments were for
- Travel & lodging$190%
- Food & beverage$22,17898%
- Education$4332%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 230 | $5,318 |
| Alkermes, Inc. | 88 | $2,273 |
| Otsuka America Pharmaceutical, Inc. | 104 | $1,906 |
| Johnson & Johnson | 87 | $1,903 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 78 | $1,692 |
| AbbVie | 87 | $1,643 |
| Takeda Pharmaceuticals U.S.A., Inc. | 110 | $1,335 |
| Lundbeck LLC | 75 | $1,305 |
| Neurocrine Biosciences, Inc. | 50 | $1,300 |
| Sunovion Pharmaceuticals Inc. | 39 | $692 |
| Indivior Inc. | 29 | $582 |
| Vanda Pharmaceuticals Inc. | 25 | $551 |
| E.r. Squibb & Sons, L.L.C. | 17 | $420 |
| Axsome Therapeutics, Inc. | 20 | $371 |
| Supernus Pharmaceuticals, Inc. | 17 | $335 |
| Corium, LLC | 12 | $219 |
| Noven Therapeutics, LLC | 5 | $118 |
| Almatica Pharma LLC | 5 | $101 |
| Adlon Therapeutics L.p. | 6 | $92 |
| Avanir Pharmaceuticals, Inc. | 4 | $89 |
| Bausch Health US, LLC | 4 | $89 |
| Idorsia Pharmaceuticals US Inc | 4 | $75 |
| Tempus AI, Inc | 2 | $47 |
| Tris Pharma Inc | 2 | $40 |
| Ironshore Pharmaceuticals Inc. | 2 | $35 |
| Merck | 2 | $35 |
| Eisai Inc. | 2 | $32 |
| Tonix Medicines, Inc. | 1 | $17 |
| OWP Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,629 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 17 | $151,875 |
| AristadaAripiprazole Lauroxil | 40 | $130,508 |
| IngrezzaValbenazine Tosylate | 14 | $112,654 |
| TrintellixVortioxetine Hydrobromide | 56 | $34,876 |
| BelsomraSuvorexant | 21 | $11,495 |
| Aripiprazole | 177 | $8,649 |
| Quetiapine Fumarate | 512 | $7,595 |
| VyvanseLisdexamfetamine Dimesylate | 19 | $7,298 |
| Paliperidone ErPaliperidone | 32 | $4,171 |
| Bupropion XlBupropion Hcl | 246 | $3,990 |
| Duloxetine Hcl | 301 | $3,337 |
| Buspirone Hcl | 332 | $3,218 |
| Trazodone Hcl | 577 | $3,207 |
| Asenapine Maleate | 17 | $3,187 |
| Lurasidone Hcl | 12 | $2,466 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $5,318 | $151,87517 claims |
| Alkermes, Inc.Aristada | $2,273 | $130,50840 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,300 | $112,65414 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $1,335 | $42,17475 claims |
| MerckBelsomra | $35 | $11,49521 claims |
| Almatica Pharma LLCSertraline Hcl | $101 | $1,360252 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Claremont
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- Samantha PerkinsAnaheim$49K
- Yvette ElpidioOrange$43K
- Sarah KoLos Angeles$34K
- Jonathan LlamasPasadena$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.